References
1. Carroll D., Daszak P., Wolfe N.D., Gao G.F., et al. The Global Virome Project Expanded viral discovery can improve mitigation. Science. 2018; 359 (6378): 872–4. DOI: 10.1126/science.aap7463
2. MERS outbreaks. Available from: http://www.emro.who.int (retrieved 15 April 2020)
3. Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int (Retrieved 15 April 2020)
4. WHO. European regional buro. http://www.euro.who.int/ru/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic (in Russian)
5. https://www.worldometers.info/coronavirus/#countries
6. Temporary guidelines (TMR) of the Ministry of Health of the Russian Federation “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, version 7 от 03.06.2020 https://base.garant.ru/74212510/
(in Russian)
7. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209: 107512. DOI: https://doi.org/10.1016/j.pharmthera.2020.107512
8. Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93 (7): 449–63. DOI: https://doi.org/10.2183/pjab.93.027
9. Yasukawa M. Clinical study of favipiravir for patients with severe fever with thrombocytopenia syndrome. 2016. In UMIN000022398 https://upload.umin.ac.jp/cgi-openbin/ctr_e/ctr_view.cgi?recptno=R000033194
10. Delang L., Abdelnabi R., Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153: 85–94.
11. Rocha-Pereira J., Jochmans D., Dallmeier K., Leyssen P., et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012; 424: 777–80. DOI:https://doi.org/10.1016/j.bbrc.2012.07.034
12. Zmurko J., Marques R.E., Schols D., Verbeken E., et al. The viral polymerase Inhibitor 7-deaza-2’-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays DISEASE progression in a robust mouse infection model. PLoS Negl Trop Dis. 2016. DOI: https://doi.org/10.1371/journal.pntd.0004695
13. Delang L., et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. 2014; 69: 2770–84. DOI: https://doi.org/10.1093/jac/dku209
14. Safronetz D., et al. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013; 57: 4673–80.
15. Sissoko D., Laouenan C, Folkesson E., M’Lebing A.B., et al. Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016; 13 (3): e1001967.
16. Furuta Y., et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005; 49: 981–6.
17. Naesens L., et al. Role of human hypoxanthine Guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol. 2013; 84: 615–29.
18. Fang Q., Wang D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir, Biosafety and Health, 2019. DOI: http://dx.doi.org/10.1016/j.bsheal.2020.04.004
19. Avigan, tablet 200 mg. Report on the Deliberation Results. 2014. [Electronic resource]. https://www.pmda.go.jp/files/000210319.pdf 20. Nagata T., Lefor A.K., Hasegawa M., Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015; 9 (1): 79–81. DOI: 10.1017/dmp.2014.1
21. Astahova A.V., Lepahin V.K., Adverse reactions and safety controls. Drug safety and pharmacovigilance. 2009; (2): 2–22.
22. Eliseeva E.V., Feoktistova Ju.V. Analysis of pharmacotherapy in pregnant women. Drug safety and pharmacovigilance. 2, 2009, 23-28.
23. Pilkington V., et al. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020; 6 (2): 45–51.
24. Kumagai Y., Murakawa Y., Hasunuma T., Aso M., et al. Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther.2015; 53: 866–74. DOI: 10.5414/CP202388
25. Zhao Y., Harmatz J.S., Epstein C.R., et al. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol. 2015; 80 (5): 1076–85. DOI: 10.1111/bcp.12644
26. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research.2020; 30: 269–71. DOI: https://doi.org/10.1038/s41422-020-0282-0
27. Chen C., et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.03.17.20037432
28. Cai Q., et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. 2020. DOI: https://doi.org/10.1016/j.eng.2020.03.007
29. www.Grls.rosminzdrav.ru
30. COVID-19 Therapeutic Trial Synopsis, Draft Feb-18.2020 [Digital source]. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf
31. Resuscitation patient amid COVID-19 pandemic. DOI: https://cardioweb.ru/news/item/2201-reanimatsionnyj-bolnoj-v-usloviyakh-pandemii-covid-19 (in Russian)
32. Favipiravir Observational Study Group, Preliminary Report of the Favipiravir Observational Study in Japan (2020/5/15). [Electronic resource] https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf (date of the application: 16.08.2020)